Summary by Ground NewsVerve Therapeutics says its experimental gene-editing treatment for a common form of heart disease was placed on clinical hold by the FDA. The Cambridge, Mass.-based biotech had submitted a request to the FDA in October to allow participants in the U.S. to receive the CRISPR-based treatment.
Published 3 months ago
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe
Time & Location
Sources are mostly out of (0)